Atosiban as a tocolytic for the treatment of spontaneous preterm labor

References

• Magowan BA, Bain M, Juszczak E, Mcinneny K. Neonatal mortality amongst Scottish preterm singleton births (1985–1994). Br. J. Obstet. Gynaecol.105(9), 1005–1010 (1998).
   PubMedGoogle Scholar
• Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR; The Epicure Study Group. Neurologic and developmental disability after extremely preterm birth. N. Engl. J. Med.343(6), 378–384 (2000).
   PubMed Web of Science ®Google Scholar
• Villar J, Ezcurra EJ. Pre-term delivery syndrome: the unmet need. New perspectives for the effective treatment of pre-term labour – an international consensus. Res. Clin. Forums16(3), 169–138 (1994).
   Google Scholar
• Keirse MJ. New perspectives for the effective treatment of preterm labor. Am. J. Obstet. Gynecol.173(2), 618–628 (1995).
   PubMed Web of Science ®Google Scholar
• Petrou S. The economic consequences of preterm birth during the first 10 years of life. Br. J. Obstet. Gynaecol.112(Suppl.), 110–115 (2005).
   Google Scholar
• Finnstrom O, Olausson PO, Sedin G et al. The Swedish national prospective study on extremely low birthweight (ELBW) infants. Incidence, mortality, morbidity and survival in relation to level of care. Acta Paediatr.86(5), 503–511 (1997).
   PubMed Web of Science ®Google Scholar
• Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database. Syst. Rev.3, CD004454 (2006).
   PubMed Web of Science ®Google Scholar
• Lamont RF, Dunlop PD, Crowley P, Levene MI, Elder MG. Comparative mortality and morbidity of infants transferred in utero or postnatally. J. Perinat. Med.11(4), 200–203 (1983).
   PubMed Web of Science ®Google Scholar
• Besinger RE, Iannucci TA. Tocolytic therapy. In: Preterm Labor. Elder MG, Romero R, Lamont RF (Eds). Churchill Livingstone, NY, USA, 243–297 (1997).
   Google Scholar
• Lamont RF. Evidence-based labour-ward guidelines for the diagnosis, management and treatment of spontaneous preterm labour. J. Obstet. Gynaecol.23(5), 469–478 (2003).
   PubMedGoogle Scholar
• Mittendorf R, Pryde PG. A review of the role for magnesium sulphate in preterm labour. Br. J. Obstet. Gynaecol.112(Suppl.) 184–188 (2005).
   Google Scholar
• Grimes DA, Nanda K. Magnesium sulfate tocolysis: time to quit. Obstet. Gynecol.108(4), 986–989 (2006).
   PubMed Web of Science ®Google Scholar
• Spellacy WN, Cruz AC, Birk SA, Buhi WC. Treatment of premature labor with ritodrine: a randomized controlled study. Obstet. Gynecol.54(2), 220–223 (1979).
   PubMed Web of Science ®Google Scholar
• The Canadian Preterm Labor Investigators Group. Treatment of preterm labor with the β-adrenergic agonist ritodrine. N. Engl. J. Med.327(5), 308–312 (1992).
   PubMed Web of Science ®Google Scholar
• Leveno KJ, Cunningham FG. b-adrenergic agonists for preterm labor. N. Engl. J. Med.327(5), 349–351 (1992).
   PubMed Web of Science ®Google Scholar
• Lamont RF. The pathophysiology of pulmonary oedema with the use of β-agonists. Br. J. Obstet. Gynaecol.107(4), 439–444 (2000).
   Google Scholar
• King JF, Grant A, Keirse MJ, Chalmers I. b-mimetics in preterm labour: an overview of the randomized controlled trials. Br. J. Obstet. Gynaecol.95(3), 211–222 (1988).
   PubMedGoogle Scholar
• Valenzuela GJ, Sanchez-Ramos L, Romero R et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. Am. J. Obstet. Gynecol.182(5), 1184–1190 (2000).
   PubMed Web of Science ®Google Scholar
• Royal College of Obstetricians and Gynaecologists. β-agonists for the Care of Women in Labour. Guideline No 1. RCOG Press, London, UK (1997).
   Google Scholar
• Royal College of Obstetricians and Gynaecologists. Tocolytic Drugs for Women in Preterm Labour. Clinical Guideline No. 1(B). RCOG Press, London, UK (2002).
   Google Scholar
• Lamont RF, Khan KS, Beattie B et al. The quality of nifedipine studies used to assess tocolytic efficacy: a systematic review. J. Perinat. Med.33(4), 287–295 (2005).
   PubMed Web of Science ®Google Scholar
• van Geijn HP, Lenglet JE, Bolte AC. Nifedipine trials: effectiveness and safety aspects. Br. J. Obstet. Gynaecol.112(Suppl.) 179–183 (2005).
   Google Scholar
• Bal L, Thierry S, Brocas E, Adam M, van de La, Tenaillon A. Pulmonary edema induced by calcium-channel blockade for tocolysis. Anesth. Analg.99(3), 910–911 (2004).
   PubMed Web of Science ®Google Scholar
• Hodges R, Barkehall-Thomas A, Tippett C. Maternal hypoxia associated with nifedipine for threatened preterm labour. Br. J. Obstet. Gynaecol.111(4), 380–381 (2004).
   Google Scholar
• Oei SG, Oei SK, Brolmann HA. Myocardial infarction during nifedipine therapy for preterm labor. N. Engl. J. Med.340(2), 154 (1999).
   PubMed Web of Science ®Google Scholar
• Parasuraman R, Gandhi MM, Liversedge NH. Nifedipine tocolysis associated atrial fibrillation responds to DC cardioversion. Br. J. Obstet. Gynaecol.113(7), 844–845 (2006).
   Google Scholar
• Vaast P, Dubreucq-Fossaert S, Houfflin-Debarge V et al. Acute pulmonary oedema during nicardipine therapy for premature labour; report of five cases. Eur. J. Obstet. Gynecol. Reprod. Biol.113(1), 98–99 (2004).
   PubMed Web of Science ®Google Scholar
• van Veen AJ, Pelinck MJ, van Pampus MG, Erwich JJ. Severe hypotension and fetal death due to tocolysis with nifedipine. Br. J. Obstet. Gynaecol.112(4), 509–510 (2005).
   Google Scholar
• Verhaert D, Van AR. Acute myocardial infarction during pregnancy. Acta Cardiol.59(3), 331–339 (2004).
   PubMed Web of Science ®Google Scholar
• Law HD, du Vigneaud V. Synthesis of 2-p-methoxyphenylalanine oxytocin (O-methyl-oxytocin) and some observations on its pharmacological behaviour. J. Am. Chem. Soc.82, 4579–4581 (1960).
   Google Scholar
• Melin P, Vilhardt H, Lindeberg G, Larsson LE, Akerlund M. Inhibitory effect of O-alkylated analogues of oxytocin and vasopressin on human and rat myometrial activity. J. Endocrinol.88(2), 173–180 (1981).
   Google Scholar
• Melin P, Trojnar J, Johansson B, Vilhardt H, Akerlund M. Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J. Endocrinol.111(1), 125–131 (1986).
   PubMed Web of Science ®Google Scholar
• Ryden G, Andersson RG, Berg G, Karlsson SG, Oscarsson Y. Binding of four oxytocin analogues to myometrial oxytocin and arginine-vasopressin binding sites in pregnant women. Gynecol. Obstet. Invest.29(1), 6–9 (1990).
   Google Scholar
• Lopez BA, Phipps SL, Rosevear SK, Turnbull AC. Mechanism of action of the oxytocin antagonist 1-deamino-2-d-Tyr-(OEt)-4-Thr-8-Orn-oxytocin. Br. J. Obstet. Gynaecol.96(9), 1108–1110 (1989).
   Google Scholar
• Thornton S, Gillespie JI, Anson LC, Greenwell JR, Melin P, Dunlop W. The effect of the oxytocin antagonists, CAP 476 and F327, on calcium mobilisation in single cultured human myometrial cells. Br. J. Obstet. Gynaecol.100(6), 581–586 (1993).
   Google Scholar
• Phaneuf S, Asboth G, Mackenzie IZ, Melin P, Lopez BA. Effect of oxytocin antagonists on the activation of human myometrium in vitro: atosiban prevents oxytocin-induced desensitization. Am. J. Obstet. Gynecol.171(6), 1627–1634 (1994).
   PubMed Web of Science ®Google Scholar
• Engstrom T, Atke A, Vilhardt H. Oxytocin receptors and contractile response of the myometrium after long term infusion of prostaglandin F2a, indomethacin, oxytocin and an oxytocin antagonist in rats. Regul. Pept.20(1), 65–72 (1988).
   PubMedGoogle Scholar
• Hageman WE, Demarest KT, Tolman EL, Peterson PA. in vitro uterine contractility studies with RWJ-22164–22000 (atosiban). Internal report no. 419965:2 DD-96016 (1996).
   Google Scholar
• Kinsler VA, Thornton S, Ashford ML, Melin P, Smith SK. The effect of the oxytocin antagonists F314 and F792 on the in vitro contractility of human myometrium. Br. J. Obstet. Gynaecol.103(4), 373–375 (1996).
   Google Scholar
• Giussani DA, Jenkins SL, Mecenas CA et al The oxytocin antagonist atosiban prevents androstenedione-induced myometrial contractions in the chronically instrumented, pregnant rhesus monkey. Endocrinology137(8), 3302–3307 (1996).
   Google Scholar
• Hahn DW, Mcguire JL, Vanderhoof M, Ericson E, Pasquale SA. Evaluation of drugs for arrest of premature labor in a new animal model. Am. J. Obstet. Gynecol.148(6), 775–778 (1984).
   Google Scholar
• Jenkin G. Oxytocin and prostaglandin interactions in pregnancy and at parturition. J Reprod. Fertil.45(Suppl.), 97–111 (1992).
   Google Scholar
• Akerlund M, Hauksson A, Lundin S, Melin P, Trojnar J. Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women. Br. J. Obstet. Gynaecol.93(1), 22–27 (1986).
   Google Scholar
• Hauksson A, Akerlund M, Melin P. Uterine blood flow and myometrial activity at menstruation, and the action of vasopressin and a synthetic antagonist. Br. J. Obstet. Gynaecol.95(9), 898–904 (1988).
   Google Scholar
• Akerlund M. Can primary dysmenorrhea be alleviated by a vasopressin antagonist? Results of a pilot study. Acta Obstet. Gynecol. Scand.66(5), 459–461 (1987).
   PubMed Web of Science ®Google Scholar
• Akerlund M, Stromberg P, Hauksson A et al. Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot study. Br. J. Obstet. Gynaecol.94(11), 1040–1044 (1987).
   PubMedGoogle Scholar
• Andersen LF, Lyndrup J, Akerlund M, Melin P. Oxytocin receptor blockade: a new principle in the treatment of preterm labor? Am. J. Perinatol.6(2), 196–199 (1989).
   PubMed Web of Science ®Google Scholar
• Eriksson H, Bjorgell P, Akerlund M, Hauksson A, Melin P. Effects of a tocolytic oxytocin analogue on lipid and carbohydrate metabolism. Gynecol. Obstet. Invest.29(2), 97–100 (1990).
   Google Scholar
• Lundin S, Akerlund M, Fagerstrom PO, Hauksson A, Melin P. Pharmacokinetics in the human of a new synthetic vasopressin and oxytocin uterine antagonist. Acta Endocrinol. (Copenh.)112(4), 465–472 (1986).
   Google Scholar
• Lundin S, Broeders A, Melin P. Pharmacokinetic properties of the tocolytic agent Mpa1, D-Tyr(Et)2, Thr4, Orn8-oxytocin (antocin) in healthy volunteers. Clin. Endocrinol. (Oxf.)39(3), 369–374 (1993).
   Google Scholar
• Goodwin TM, Millar L, North L, Abrams LS, Weglein RC, Holland ML. The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. Am. J. Obstet. Gynecol.173(3 Pt 1), 913–917 (1995).
   PubMed Web of Science ®Google Scholar
• Kahn J. Rising dose tolerance and safety evaluation of atosiban (RWJ 22164) in normal female subjects (Protocol I88–012). Internal report of the RW Johnson Pharmaceutical Research Institute, Document no. 20870:1 (1993).
   Google Scholar
• Kahn J. Safety and tolerance evaluation of a 12 hour infusion of atosiban (RWJ 22164) in normal female volunteers (Protocol I88–084). Internal report of the RW Johnson Pharmaceutical Research Institute, Document no. 354474:1 (1993).
   Google Scholar
• Lasseter KC. A double-blind pharmacokinetic and safety study of 120 hours of infusion of Antocin (RWJ 22164) in normal female volunteers (Protocol N93–046). Internal report of the RW Johnson Pharmaceutical Research Institute, Document no. 354474:1 (1995).
   Google Scholar
• Valenzuela GJ, Craig J, Bernhardt MD, Holland ML. Placental passage of the oxytocin antagonist atosiban. Am. J. Obstet. Gynecol.172(4 Pt 1), 1304–1306 (1995).
   PubMed Web of Science ®Google Scholar
• Christopher RJ. Determination of the in vitro plasma protein binding of atosiban (RWJ 22164–22021) and distribution into human erythrocytes (DM92–04). Scientific memo of the RW Johnson Pharmaceutical Research Institute, Document no. 397084:1 (1996).
   Google Scholar
• McKown LA, Wu WN. Metabolism of atosiban following a bolus and i.v. infusion dose to female volunteers (study DM 95350). Internal report of the RW Johnson Pharmaceutical Research Institute, Document no. 393955:1 (1996).
   Google Scholar
• McKown LA, Wu WN. Relative plasma concentrations of the atosiban M1 metabolite at steady-state following intravenous bolus and infusion doses to normal female volunteers, and in maternal and fetal plasma samples following intravenous infusion to healthy pregnant women (Study DM 96318). Internal report of the RW Johnson Pharmaceutical Research Institute, Document no. 408949:1 (1996).
   Google Scholar
• Goodwin TM, Paul R, Silver H et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. Am. J. Obstet. Gynecol.170(2), 474–478 (1994).
   PubMed Web of Science ®Google Scholar
• Goodwin TM, Valenzuela G, Silver H, Hayashi R, Creasy GW, Lane R. Treatment of preterm labor with the oxytocin antagonist atosiban. Am. J. Perinatol.13(3), 143–146 (1996).
   PubMed Web of Science ®Google Scholar
• Goodwin TM, Valenzuela GJ, Silver H, Creasy G. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Atosiban Study Group. Obstet. Gynecol.88(3), 331–336 (1996).
   PubMed Web of Science ®Google Scholar
• Romero R, Sibai BM, Sanchez-Ramos L et al An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am. J. Obstet. Gynecol.182(5), 1173–1183 (2000).
   PubMed Web of Science ®Google Scholar
• Moutquin JM, Sherman D, Cohen H et al Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am. J. Obstet. Gynecol.182(5), 1191–1199 (2000).
   PubMed Web of Science ®Google Scholar
• Cabrol D, Gillet JY, Madelenat P. Treatment of preterm labor with the oxytocin antagonist atosiban: a double-blind, randomized, controlled comparison with salbutamol. Eur. J. Obstet. Gynecol. Reprod. Biol.98(2), 177–185 (2001).
   PubMed Web of Science ®Google Scholar
• Marsal K, Fisk NM, Calder AA. The oxytocin antagonist atosiban versus the – agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study. Acta Obstet. Gynecol. Scand.80(5), 413–422 (2001).
   PubMed Web of Science ®Google Scholar
• Moutquin JM, Cabrol D, Fisk NM. Effectiveness and safety of the oxytocin antagonist atosiban versus b-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus β-agonists Study Group. Br. J. Obstet. Gynaecol.108(2), 133–142 (2001).
   Google Scholar
• Husslein P, Quartarolo JP. Review of clinical experience with atosiban and the Tractocile Efficacy Assessment Survey in Europe (TREASURE) study protocol. Int. J. Clin. Pract.57(2), 121–127 (2003).
   PubMed Web of Science ®Google Scholar
• Husslein P, Roura L, Dudenhausen J et al. Clinical practice evaluation of atosiban in preterm labour management in six European countries. Br. J. Obstet. Gynaecol.113(Suppl.) 114(8), 1043 (2006).
   Google Scholar
• Kashanian M, Akbarian AR, Soltanzadeh M. Atosiban and nifedipine for the treatment of preterm labor. Int. J. Gynaecol. Obstet.91(1), 10–14 (2005).
   PubMed Web of Science ®Google Scholar
• Al-Omari WR, Al-Shammaa HB, Al-Tikriti EM, Ahmed KW. Atosiban and nifedipine in acute tocolysis: a comparative study. Eur. J. Obstet. Gynecol. Reprod. Biol.128(1–2), 129–134 (2006).
   PubMed Web of Science ®Google Scholar
• Ingemarsson I. Tocolytic therapy and clinical experience. Combination therapy. Br. J. Obstet. Gynaecol.112(Suppl. 1) 89–93 (2005).
   Google Scholar
• Lamont RF. The development and introduction of anti-oxytocic tocolytics. Br. J. Obstet. Gynaecol.110(Suppl. 20), 108–112 (2003).
   Google Scholar
• Lyndrup J, Lamont RF. The choice of tocolytic for the treatment of preterm labour: a critical evaluation of nifedipine versus atosiban. Expert Opin. Invest. Drugs16(6), 843–853 (2007).
   PubMed Web of Science ®Google Scholar
• Goodwin T. Regulatory and methodologic challenges to tocolytic development. Br. J. Obstet. Gynaecol.113(Suppl. 3), 100–104 (2006).
   Google Scholar